The EC90 of Remifentanil Blunting Hemodynamic Changes to Head Fixation in the Patients Undergoing Neurosurgery
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- mean arterial blood pressure
Study Overview
Brief Summary
The purpose of this study is to estimate the EC90 of remifentanil blunting hemodynamic changes to head fixation in the patients undergoing neurosurgery.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •patients undergoing neurosurgery that require head fixation with mayfield head holder
- •patients who agree to our study
Exclusion Criteria
- •patients who don't agree to our study
- •BMI<16.0 or BMI>30
- •cardiovascular disease, pulmonary disease, renal disease
- •alcoholic abuser or drug abuser
- •patients who takes any drug having an influence on cardiovascular system or sympathetic nervous system
- •any use of local anesthetics or drugs which have an influence on cardiovascular system from beginning of induction to peri-fixation period
Arms & Interventions
neurosurgery with fixation
Intervention: remifentanil (Drug)
Outcomes
Primary Outcomes
mean arterial blood pressure
Time Frame: peri-fixation periord
mean arterial blood pressure will be recorded at 2 minutes before fixation, 1 minute before fixation, highest value during immediately post-fixation periord, 1 minute after fixation, 2 minutes after fixation, 3 minutes after fixation, 4 minutes after fixation and 5 minutes after fixation.
heart rate
Time Frame: peri-fixation periord
heart rate will be recorded at 2 minutes before fixation, 1 minute before fixation, highest value during immediately post-fixation periord, 1 minute after fixation, 2 minutes after fixation, 3 minutes after fixation, 4 minutes after fixation and 5 minutes after fixation.
Secondary Outcomes
No secondary outcomes reported
Investigators
Jae-Hyon Bahk, MD, PhD
professor
Seoul National University Hospital